ARCT Quote, Financials, Valuation and Earnings

bluebird bio has a net margin of -55.25% compared to Arcturus Therapeutics Holdings's net margin of -75.09%. Arcturus Therapeutics Holdings's return on equity of -27.08% beat bluebird bio's return on equity of -1125.51%.

Arcturus Therapeutics Holdings has a consensus price target of $66.80, signalling upside risk potential of 433.13%. On the other hand bluebird bio has an analysts' consensus of $8.00 which suggests that it could grow by 60.97%. Given that Arcturus Therapeutics Holdings has higher upside potential than bluebird bio, analysts believe Arcturus Therapeutics Holdings is more attractive than bluebird bio.

Arcturus Therapeutics Holdings has a beta of 2.298, which suggesting that the stock is 129.81% more volatile than S&P 500. In comparison bluebird bio has a beta of 0.331, suggesting its less volatile than the S&P 500 by 66.903%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. bluebird bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. bluebird bio pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $25.5M, which are smaller than bluebird bio quarterly revenues of $38.7M. Arcturus Therapeutics Holdings's net income of -$14.1M is higher than bluebird bio's net income of -$29.1M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while bluebird bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.58x versus 0.46x for bluebird bio. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -55.25% compared to Arcturus Therapeutics Holdings's net margin of --. Arcturus Therapeutics Holdings's return on equity of -27.08% beat Perspective Therapeutics's return on equity of --.

Arcturus Therapeutics Holdings has a consensus price target of $66.80, signalling upside risk potential of 433.13%. On the other hand Perspective Therapeutics has an analysts' consensus of $13.8214 which suggests that it could grow by 437.8%. Given that Perspective Therapeutics has higher upside potential than Arcturus Therapeutics Holdings, analysts believe Perspective Therapeutics is more attractive than Arcturus Therapeutics Holdings.

Arcturus Therapeutics Holdings has a beta of 2.298, which suggesting that the stock is 129.81% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.093, suggesting its more volatile than the S&P 500 by 9.29%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $25.5M, which are larger than Perspective Therapeutics quarterly revenues of --. Arcturus Therapeutics Holdings's net income of -$14.1M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.58x versus 18.11x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -55.25% compared to Arcturus Therapeutics Holdings's net margin of -35.79%. Arcturus Therapeutics Holdings's return on equity of -27.08% beat Protalix BioTherapeutics's return on equity of 10.9%.

Arcturus Therapeutics Holdings has a consensus price target of $66.80, signalling upside risk potential of 433.13%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 803.23%. Given that Protalix BioTherapeutics has higher upside potential than Arcturus Therapeutics Holdings, analysts believe Protalix BioTherapeutics is more attractive than Arcturus Therapeutics Holdings.

Arcturus Therapeutics Holdings has a beta of 2.298, which suggesting that the stock is 129.81% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.210, suggesting its less volatile than the S&P 500 by 120.951%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $25.5M, which are larger than Protalix BioTherapeutics quarterly revenues of $10.1M. Arcturus Therapeutics Holdings's net income of -$14.1M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Protalix BioTherapeutics's PE ratio is 38.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.58x versus 2.18x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sangamo Therapeutics has a net margin of -55.25% compared to Arcturus Therapeutics Holdings's net margin of -475.33%. Arcturus Therapeutics Holdings's return on equity of -27.08% beat Sangamo Therapeutics's return on equity of -269.87%.

Arcturus Therapeutics Holdings has a consensus price target of $66.80, signalling upside risk potential of 433.13%. On the other hand Sangamo Therapeutics has an analysts' consensus of $4.10 which suggests that it could grow by 781.72%. Given that Sangamo Therapeutics has higher upside potential than Arcturus Therapeutics Holdings, analysts believe Sangamo Therapeutics is more attractive than Arcturus Therapeutics Holdings.

Arcturus Therapeutics Holdings has a beta of 2.298, which suggesting that the stock is 129.81% more volatile than S&P 500. In comparison Sangamo Therapeutics has a beta of 1.456, suggesting its more volatile than the S&P 500 by 45.634%.

Arcturus Therapeutics Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sangamo Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcturus Therapeutics Holdings pays -- of its earnings as a dividend. Sangamo Therapeutics pays out -- of its earnings as a dividend.

Arcturus Therapeutics Holdings quarterly revenues are $25.5M, which are larger than Sangamo Therapeutics quarterly revenues of $6.4M. Arcturus Therapeutics Holdings's net income of -$14.1M is higher than Sangamo Therapeutics's net income of -$30.6M. Notably, Arcturus Therapeutics Holdings's price-to-earnings ratio is 8.50x while Sangamo Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcturus Therapeutics Holdings is 2.58x versus 1.55x for Sangamo Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.